Home News Page 3

News

SOPHiA Genetics and ADC Therapeutics Partner for Biomarker Discovery in Pivotal Phase II Clinical...

ADC Therapeutics and SOPHiA GENETICS have entered into a collaboration to identify genomic markers associated with clinical response to...
A new technology enables a simple way of connecting the cytsteine residues (SH) of a tumor-sensing antibody (yellow) to the cytotoxic payload. The emerging linker is highly stable during blood circulation and enables therefore a safe transport to the tumor side. Image courtesy: Barth van Rossum/FMP

A Superglue for ADCs: Connecting the Cytsteine Residues of a Tumor-sensing Antibody to a...

The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU) hve developed an innovative technology designed to make...
Nanolive video by NBE Therapeutics

5 Things You Need To Know About ADCs – August 8, 2019

Hello again everyone, It's time again for another update on the world of ADC. There's been lots of good stuff...
One red Dutch tulip

Trastuzumab Duocarmazine for Treatment of HER2-Expressing Breast Cancer

Trastuzumab duocarmazine* (SYD985; Synthon) is a novel antibody-drug conjugate composed of the recombinant humanized anti-epidermal growth factor receptor 2...
Seattle Genetics

5 Things You Need To Know This Week About ADCs – July 27, 2019

This is the second article in my series of updates about the goings on in the world of ADCs...
Featured Image: Lonza, Visp, Switzerland. Courtesy: © 2010 - 2018 Lonza, Visp, Switzerland. Used with permission.

Lonza Expands Bioconjugation Facility for the Commercial Manufacture of Third Antibody-drug Conjugate

Lonza, the Swiss Contract Development and Manufacturing Organization (CDMO), has confirmed the start of expansion to its bioconjugation facility...

Abzena Confirms Successful Technical Transfer of Synaffix’s GlycoConnect™ and HydraSpace™ Technologies

Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix's technologies...
ADC Biotechnology in Deeside, North-Wales, UK. With the availability of a new cleanroom, the company continues its focus on antibody-drug conjugates (ADCs) and developing new process technologies to speed up, simplify and significantly lower the production costs of the latest generation of anticancer blockbuster drugs.

WHP Completes a New State of the Art Cleanroom for ADC Bio

The production of novel antibody-drug conjugates at ADC Biotechnology’s North Wales, United Kingdom, manufacturing plant has been boosted with...
Astellas Pharma. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Astellas and Seattle Genetics file BLA for Enfortumab Vedotin

Japanese drugmaker Astellas Pharma and Seattle Genetics confirmed the submission of a Biologics License Application (BLA) for accelerated approval...

5 Things You Need To Know About ADCs This Week – July 15, 2019

In this article I want to discuss the 5 Things happening in the world of ADCs this week that...

FEATURED RESOURCES